The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
The clinical development of MEK inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Differential regulation and properties of MAPKs
Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Meloche, S., & Pouysségur, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210414 · Cited by 1,091
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
The MEK/ERK cascade: From signaling specificity to diverse functions
Shaul, Y. D., & Seger, R. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.005 · Cited by 940
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
RAS Interaction with PI3K: More Than Just Another Effector Pathway
Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Regulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
Marais, R., Light, Y., Paterson, H. F., & Marshall, C. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07316.x · Cited by 612
Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., Rominger, C. M., Erskine, S., Fisher, K. E., Yang, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2200 · Cited by 587
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D., Brandhuber, B. J., Gross, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578
Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, L., Chow, L., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 570
Self-citationInfante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Sun, P., Moy, C., Szabo, S. A., Roadcap, L. T., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70269-3 · Cited by 546
Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 477
Raf-1 protein kinase is required for growth of induced NIH/3T3 cells
Kolch, W., Heidecker, G., Lloyd, P., & Rapp, U. R. (1991) · Nature · doi:10.1038/349426a0 · Cited by 474
Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C
Marais, R., Light, Y., Mason, C., Paterson, H., Olson, M. F., & Marshall, C. J. (1998) · Science · doi:10.1126/science.280.5360.109 · Cited by 441
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Regulation and Role of Raf-1/B-Raf Heterodimerization
Rushworth, L. K., Hindley, A. D., O'Neill, E., & Kolch, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2262-2272.2006 · Cited by 418
Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
Self-citationBRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2707 · Cited by 397
Selective requirement for MAP kinase activation in thymocyte differentiation
Alberola-lla, J., Forbush, K. A., Seger, R., Krebs, E. G., & Perlmutter, R. M. (1995) · Nature · doi:10.1038/373620a0 · Cited by 389
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
Friday, B. B., & Adjei, A. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4790 · Cited by 374
Self-citationSequential protein kinase reactions controlling cell growth and differentiation
Johnson, G. L., & Vaillancourt, R. R. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90141-4 · Cited by 335
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K., Price, S., Heald, R., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 319
Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1
O'Neill, E., Rushworth, L., Baccarini, M., & Kolch, W. (2004) · Science · doi:10.1126/science.1103233 · Cited by 317
Chen, J., Fujii, K., Zhang, L., Roberts, T., & Fu, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141224398 · Cited by 316
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O'Neil, B. H., Balsom, S., Balint, C., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 303
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.054 · Cited by 289
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 278
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 252
Haass, N. K., Sproesser, K., Nguyen, T. K., Contractor, R., Medina, C. A., Nathanson, K. L., Herlyn, M., & Smalley, K. S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1440 · Cited by 244
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Ritt, D. A., Monson, D. M., Specht, S. I., & Morrison, D. K. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00569-09 · Cited by 238
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236
D'Angelo, G., Struman, I., Martial, J., & Weiner, R. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6374 · Cited by 227
Banerji, U., Camidge, D. R., Verheul, H. M. W., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M. E., Timmer-Bonte, J. N. H., Eckhardt, S. G., Lewis, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2483 · Cited by 211
New drugs in melanoma: It’s a whole new world
Eggermont, A. M. M., & Robert, C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.052 · Cited by 186
Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
Fischmann, T. O., Smith, C. K., Mayhood, T. W., Myers, J. E., Reichert, P., Mannarino, A., Carr, D., Zhu, H., Wong, J., Yang, R.-S., et al. (2009) · Biochemistry · doi:10.1021/bi801898e · Cited by 183
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
Iverson, C., Larson, G., Lai, C., Yeh, L.-T., Dadson, C., Weingarten, P., Appleby, T., Vo, T., Maderna, A., Vernier, J.-M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0679 · Cited by 183
Knauf, J. A., Kuroda, H., Basu, S., & Fagin, J. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206602 · Cited by 181
Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
Signaling from Ras to Rac and beyond: not just a matter of GEFs
Scita, G., Tenca, P., Frittoli, E., Tocchetti, A., Innocenti, M., Giardina, G., & Di Fiore, P. P. (2000) · The EMBO Journal · doi:10.1093/emboj/19.11.2393 · Cited by 170
Robert, C., Dummer, R., Gutzmer, R., Lorigan, P., Kim, K. B., Nyakas, M., Arance, A., Liszkay, G., Schadendorf, D., Cantarini, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70237-7 · Cited by 169
Rice, K. D., Aay, N., Anand, N. K., Blazey, C. M., Bowles, O. J., Bussenius, J., Costanzo, S., Curtis, J. K., Defina, S. C., Dubenko, L., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300049d · Cited by 167
Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T. E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., & Tzekova, V. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8b3a3 · Cited by 162
Hayes, D. N., Lucas, A. S., Tanvetyanon, T., Krzyzanowska, M. K., Chung, C. H., Murphy, B. A., Gilbert, J., Mehra, R., Moore, D. T., Sheikh, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0563 · Cited by 154
Martinez‐García, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S. O., Kraeber‐Bodéré, F., Rojo, F., Routier, É., Guarin, E., Xu, Z., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0742 · Cited by 152
O’Neil, B. H., Goff, L. W., Kauh, J. S. W., Strosberg, J., Bekaii‐Saab, T., Lee, R.-M., Kazi, A., Moore, D. T., Learoyd, M., Lush, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9432 · Cited by 151
Huynh, H. T., Soo, K. C., Chow, P. K. H., & Tran, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0436 · Cited by 150
Role of RAS in the Regulation of PI 3-Kinase
Castellano, E., & Downward, J. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_56 · Cited by 149
Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., & Adjei, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1430 · Cited by 146
Self-citationBennouna, J., Láng, I., Valladares‐Ayerbes, M., Boér, K., Adenis, A., Escudero, P., Kim, T. Y., Pover, G. M., Morris, C. D., & Douillard, J.-Y. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9392-8 · Cited by 141
Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T. A., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3476 · Cited by 141
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Wang, S., Ghosh, R. N., & Chellappan, S. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7487 · Cited by 138
Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Jing, J., Greshock, J. D., Holbrook, J. D., Gilmartin, A. G., Zhang, X., McNeil, E., Conway, T. M., Moy, C. H., Laquerre, S. G., Bachman, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0505 · Cited by 135
COSMIC: the catalogue of somatic mutations in cancer
Bindal, N., Forbes, S. A., Beare, D. M., Gunasekaran, P., Leung, K., Kok, C. Y., Jia, M., Bamford, S., Cole, C. G., Ward, S. A., et al. (2011) · Genome biology · doi:10.1186/gb-2011-12-s1-p3 · Cited by 133
Kım, K., Kong, S., Fulciniti, M., Li, X., Song, W., Nahar, S., Burger, P., Rumizen, M. J., Podar, K., Chauhan, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08127.x · Cited by 126
Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf
Brummer, T., Naegele, H., Reth, M. G., & Misawa, Y. (2003) · Oncogene · doi:10.1038/sj.onc.1207185 · Cited by 115
Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L. D., Ko, M., Aguirre, S. A., & Younis, H. S. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0060 · Cited by 90
Rauch, J., O’Neill, E. E., Mack, B., Matthias, C., Münz, M., Kölch, W., & Gires, O. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2740 · Cited by 85
Raf-1 sets the threshold of Fas sensitivity by modulating Rok-α signaling
Piazzolla, D., Meissl, K., Kučerová, L., Rubiolo, C., & Baccarini, M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504137 · Cited by 85
Hou, P., Liu, D., & Xing, M. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0212 · Cited by 84
Camidge, D. R., Bazhenova, L. A., Salgia, R., Weiss, G. J., Langer, C. J., Shaw, A. T., Narasimhan, N. I., Dorer, D. J., Rivera, V. M., Zhang, J. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8031 · Cited by 80
Pandey, S., Théberge, J.-F., Bernier, M., & Srivastava, A. K. (1999) · Biochemistry · doi:10.1021/bi9911886 · Cited by 79
Leijen, S., Middleton, M. R., Tresca, P., Kraeber‐Bodéré, F., Dieras, V. C., Scheulen, M. E., Gupta, A., López-Valverde, V., Xu, Z., Rueger, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0868 · Cited by 74
Na, J., Furue, M. K., & Andrews, P. W. (2010) · Stem Cell Research · doi:10.1016/j.scr.2010.06.002 · Cited by 71
Weekes, C. D., Hoff, D. D. V., Adjei, A. A., Leffingwell, D. P., Eckhardt, S., Gore, L., Lewis, K. D., Weiss, G. J., Ramanathan, R. K., Dy, G. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3529 · Cited by 60
Self-citationSchmieder, R., Puehler, F., Neuhaus, R., Kissel, M., Adjei, A. A., Miner, J. N., Mumberg, D., Ziegelbauer, K. B., & Scholz, A. (2013) · Neoplasia · doi:10.1593/neo.13812 · Cited by 58
Self-citationDeming, D. A., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Eickhoff, J. C., Kolesar, J. M., Fioravanti, S., Greten, T. F., Compton, K., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-015-0314-7 · Cited by 52
Cohen, R. B., Aamdal, S., Nyakas, M., Cavallin, M., Green, D., Learoyd, M., Smith, I., & Kurzrock, R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.01.013 · Cited by 48
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
Finn, R. S., Javle, M. M., Tan, B. R., Weekes, C. D., Bendell, J. C., Patnaik, A., Khan, G. N., Laheru, D. A., Anderson, L., Christy‐Bittel, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.220 · Cited by 48
LoRusso, P. M., Shapiro, G. I., Pandya, S. S., Kwak, E. L., Jones, C. A., Belvin, M. P., Musib, L. C., de Crespigny, A. J., McKenzie, M., Gates, M. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2566 · Cited by 48
Shapiro, G. I., LoRusso, P. M., Kwak, E. L., Cleary, J. M., Musib, L. C., Jones, C. B., de Crespigny, A. J., Belvin, M. P., McKenzie, M., Gates, M. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3005 · Cited by 44
TMEM16A alternative splicing coordination in breast cancer
Ubby, I., Bussani, E., Colonna, A., Stacul, G., Locatelli, M., Scudieri, P., Galietta, L. J. V., & Pagani, F. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-75 · Cited by 42
Sequist, L. V. D., Soria, J., Gadgeel, S. M., Wakelee, H. A., Camidge, D. R., Varga, A., Fidias, P., Wozniak, A. J., Neal, J. W., Doebele, R. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2524 · Cited by 42
Lee, L., Niu, H., Rueger, R., Igawa, Y., Deutsch, J., Ishii, N., Mu, S., Sakamoto, Y., Busse‐Reid, R., Gimmi, C. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1696 · Cited by 41
MEK inhibitors: a patent review 2008 – 2010
Trujillo, J. I. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.577068 · Cited by 40
The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer
Xing, M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02332.x · Cited by 39
Delord, J., Houédé, N., Awada, A. H., Taamma, A., Faivre, S. J., Besse‐Hammer, T., Italiano, A., Vignaud, C. M. D., Donica, M., & Raymond, É. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2504 · Cited by 36
Khan, K. H., Yan, L., Mezynski, J., Patnaik, A., Moreno, V., Papadopoulos, K. P., Garrett, C. R., Ong, M., Shannon, K. A., Morosky, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e13599 · Cited by 36
Dropped head syndrome: Report of three cases during treatment with a MEK inhibitor
Chen, X., Schwartz, G. K., DeAngelis, L. M., Kaley, T. J., & Carvajal, R. D. (2012) · Neurology · doi:10.1212/wnl.0b013e318271f87e · Cited by 32
Bendell, J. C., Papadopoulos, K. P., Jones, S. F., Barrett, E., Guthrie, K., Kass, C. L., Litwiler, K. S., Napier, C., & Patnaik, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-b243 · Cited by 30
Kurzrock, R., Patnaik, A., Rosenstein, L., Fu, S. W., Papadopoulos, K. P., Smith, D. A., Falchook, G. S., Chambers, G., Gauvin, J., Naing, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3085 · Cited by 28
González, R., Ribas, A., DAUD, A. I., Pavlick, A. C., Gajewski, T. F., Puzanov, I. J., Teng, M. S. L., Chan, I. T., Choong, N. W., & McArthur, G. A. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)34336-2 · Cited by 21
Sebolt, J. S., Merriman, R. L., Omer, C. A., Tecle, H., Bridges, A. J., Klohs, W. D., Loi, C., Valik, H., Przybranowski, S. A., Meyer, M. B., et al. (2004) · Cancer Research · Cited by 20
Houédé, N., Faivre, S. J., Awada, A. H., Raymond, É., Italiano, A., Besse‐Hammer, T., Donica, M., Rejeb, N., Lüpfert, C., Ongarello, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3019 · Cited by 19
Macarulla, T. M., Tabernero, J. M., Cervantes, A. M. R., Roselló, S., Cutsem, E. V., Tejpar, S., Prenen, H., Martinelli, E., Troiani, T., Campana, F., et al. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(19)66518-x · Cited by 15
Lim, H. Y., Yen, C., Tak, W. Y., Heo, J., Choi, H. J., Lin, C.-Y., Yoon, J., Hsu, C., Rau, K., Poon, R. T. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4103 · Cited by 15
A full-length 3D structure for MAPK/ERK kinase 2 (MEK2)
Liang, H., Liu, T., Chen, F., Liu, Z., & Liu, S. (2011) · Science China Life Sciences · doi:10.1007/s11427-011-4156-z · Cited by 11
Gore, L., Lewis, K. A., Hoff, D. D. V., Weiss, G. J., Ramanathan, R., Adjei, A. A., Dy, G. K., Ma, W. W., Clendeninn, N. J., Leffingwell, D. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3007 · Cited by 11
Self-citationBecerra, C. R., Infante, J. R., Garbo, L. E., Gordon, M. S., Smith, D. A. B., Braiteh, F. S., Gandara, D. R., Jotte, R. M., Reckamp, K. L., Jankú, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3023 · Cited by 11
El-Khoueiry, A. B., Kurkjian, C. D., Semrad, T. J., Musib, L. C., Gates, M. R., Eppler, S., Chang, I., Chan, I. T., Rooney, I. A., & Bendell, J. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-b75 · Cited by 10
Britten, C. D., Wainberg, Z. A., Tabernero, J. M., Alsina, M., Leong, S., Sessa, C., Millham, R., Gallo, J. D., Siu, L. L., & Braña, I. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72156-1 · Cited by 10
Deming, D. A., Schelman, W. R., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Fioravanti, S., Greten, T. F., Eickhoff, J. C., Kolesar, J., Compton, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3103 · Cited by 9
Infante, J. R., Patnaik, A., Jones, S. F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-b128 · Cited by 8
Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.
Borad, M. J., Akerele, C., Ramanathan, R. K., Northfelt, D., Reyderman, L., Verbel, D., Feit, K., Hoff, D. D. V., & Tibes, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2505 · Cited by 8
Mala, C., Neville, N. G., Haindl, E., Bürgle, M., Schmalix, W. A., & Bevan, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13666 · Cited by 7
Research works printed but not linked: 11
- Mehra, R. et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), a3007 (2012). · doi:10.1200/jco.2012.30.15_suppl.3007
- Harding, J. J. et al. Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets) [abstract]. J. Clin. Oncol. 31 (Suppl.), a9060 (2013). · doi:10.1200/jco.2013.31.15_suppl.9060
- Jain, N, C. et al. Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML) [abstract]. J. Clin. Oncol. 30 (Suppl.), a6582 (2012).
- Hochster, H. S. et al. The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3587 (2013). · DOI
- Gupta, A. et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma [abstract]. J. Clin. Oncol. 31 (Suppl.), a9068 (2013). · doi:10.1200/jco.2013.31.15_suppl.9068
- Rosen, L. S. et al. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors [abstract]. J. Clin. Oncol. 26 (Suppl.), a14585 (2008). · doi:10.1200/jco.2008.26.15_suppl.14585
- Van Laethem, J. L. et al. A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): phase I dose-escalation results [abstract]. J. Clin. Oncol. 30 (Suppl.), a4050 (2012). · doi:10.1200/jco.2012.30.15_suppl.4050
- Infante, J. R. et al. A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas [abstract]. J. Clin. Oncol. 30 (Suppl.), a291 (2013). · doi:10.1200/jco.2013.31.4_suppl.291
- Ahmed, S. R. et al. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), TPS3117 (2012). · doi:10.1200/jco.2012.30.15_suppl.tps3117
- Sosman, J. A. et al. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma [abstract]. J. Clin. Oncol. 29 (Suppl.), TPS145 (2011). · doi:10.1200/jco.2011.29.15_suppl.tps145
- Adjei, A. A. et al. Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), a2528 (2013). · doi:10.1200/jco.2013.31.15_suppl.2528
Cited by
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain
Nikolaev, S. I., Vetiska, S., Bonilla, X., Boudreau, E., Jauhiainen, S., Rezai Jahromi, B., Khyzha, N., DiStefano, P. V., Suutarinen, S., Kiehl, T.-R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709449 · Cited by 467
Metadata
- Authors
- Zhao, Y., & Adjei, A. A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2014-05-20
- Volume
- 11
- Issue
- 7
- Pages
- 385-400
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1991401350
- Cited by
- 400
- References
- 126
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.